Conditions: Healthy
Keywords: Bioequivalence Healthy Subjects
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 26
Healthy volunteers: yes

Brief summary:
This study compared the relative bioavailability (rate and extent of absorption) of 90 mg Fluoxetine Hydrochloride Capsules by Teva Pharmaceuticals, USA with that of 90 mg PROZAC WEEKLY® Capsules by Eli Lilly and Company following a single oral dose (1 x 90 mg) in healthy adult volunteers under fasting conditions.

Detailed description:

Arms:
arm 1: 90 mg PROZAC WEEKLY® Capsules (Eli Lilly) arm 2: 90 mg Fluoxetine Hydrochloride Capsules (Teva)

Interventions: intervention 1: Fluoxetine Hydrochloride intervention 2: PROZAC WEEKLY®
Intervention descriptions: intervention 1: 90 mg Capsules intervention 2: 90 mg Capsules

Protocol document: